March 8, 2010 – AsepticSure™ Eliminates All Pathogens
AsepticSure™ Eliminates All Pathogens
San Francisco, California March 8, 2010, Medizone International, Inc. (MZEI.OB) announced today that it has successfully completed the first full round of room scale testing with its AsepticSure™ sterilization system. "Across the board", commented Dr Michael Shannon, "all pathogens of cause with HAIs were completely eliminated from stainless steel surfaces at concentrations well above 6 log. These results have confirmed the laboratory findings reported earlier this year, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment."
Work will continue on the room scale testing program in order to expand our understanding of factors that will enhance the efficiency and effectiveness of AsepticSure™, particularly when dealing with contaminated textiles in time sensitive hospital spaces.
To meet the unique challenges of hospital acquired infections, Medizone has assembled an international team of professional engineers who are finalizing design of our first pre-manufacturing prototype to be used in hospital beta testing, which will commence later this spring. Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure™ systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year.
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Current research is being conducted at Medizone’s dedicated laboratories located in Innovation Park, Queen’s University in Kingston, Ontario, Canada.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations: 415-868-0300 / web site: www.medizoneint.com